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We corctude that cardiac cacbexta is chamctarised by a marked absolute 
bone loss and a reduction of bone der~ily, possibly taadlng to increased 
fracture risk. Taking % Ideal body weight as a measure of atrophy, humora! 
catabolic factors such as TNF-a and cortisol (and possibly ethere) contribute 
partly to reduced bone mineral density. 
~ '~- -~ Vitsmin O Deficiency Is Common in Heart Failure 
Donna Mmctnt, Kefih Aareneon, Ann Foray, vicki A(~lresso, Stuart Katz, 
Elizabeth Shone. Columbia-Prebyterian Medical Center, NY, IVY 
Calcitrol (CT), the active matsbollte of Vitamin D 0tit 13) produced by the 
kidney, regulates plasma calcium (Ca) by its actions at bone, kidney end 
intestine. Recently other actions of CT have been described including rapid, 
non-genomlo activation of Ca channels in "nontmditionat" tissues. In vascular 
smco~ muscle, CT incr_~sen ~cell g ro~ and the contractile respo,-.~e to 
noreptnephfine, tn the heart, low CT has been associated with impaired 
mitochreoddal oxidative posphorylation, decreased contrantilily, and increase 
hypertrophy. V'it D status can be assessed by meast, dng soum CT or Calcidiol 
(CD, the storage form of Vit D). To evaluate Vii D status in CHF, serum CT, 
CD, parathyroid hormone (PTH), Ca, PO4, BUN, crealinine (Cr), 24 hr udnary 
Ca and Cr were measured in 84 patients. Hemedynamlo measurements, 
LVEF, peak VO2, pdodty status at transplant were also measured. The 11 
patlonts with low CD levels were more likely to be Status I (13 < 0.02), 
had lower peak VO2 (12.5 :E 3.7 vs 7.4 ± 4.9 ml/kg]mfn;p < 0.05), lower 
serum Ca (9,6 :E 0.1 vs 8.8 • 0.2 mg/dl; p < 0,001) and tendency to 
higher mean pulmonary artery pressures, The 22 patients with low CT levels 
had a significant reduction in crealinine clearance (60 :E 21 vs 39 :l: 22 
ml/min;p < 0.00!) and serum Ca (9,6 -4- 0.1 vs 9.3 :E 0.2; p < 0.05). Only 
4 paUents had Significantly reduced CD and CT levels. High PTH levels 
(> 65 pg/ml), present in 25 patients, did not correlate with renal function 
or Vii D levels. LVEF was s'~gar in low Vit D and high PTH groups, lo 
conclusion, Vit D deficiency is a common finding in patients with CHE CD 
deficiency correlates with the severity of the disease and is probably related 
to combination of dietary factors, malabsorption and low sunlight exposure. 
CT deficiency is closely associated with renal insufficiency. Though major 
hemodynemie differences were not found between ormal and Vit 13 deficient 
patients, further investigstion is warranted to determine if Vit D administration 
has therapeutic benefit in this patient population. 
~"~ High Circulating Levels of  Cardiac Tfoponin I in 
Human Congeative Heart Failure 
Emile Missov, Chadas Calzolari 1 Bernard Pau 2. Department of Cardiology, 
Ueiversity Hospital, Montpellier, France; 1 Sanofi Recherche, Montpeltier, 
France; 2 CNRS UMR 9921, Montt~llier, France 
Neuro-endecdne and immune dysfunction have been extensively reported in 
congestive heart failure (CHF) patients, However, the biochemical diagnosis 
of CHF lacks specificity. Cardiac troponin I (cTnl) is a regulatory protein 
uniquely located in the myocardium with 31 additional amino acid residues 
at the N-terminal and more than 40% dissimilarity with the skeletal muscle 
Isoforms. in the present study, we postulated that end-stage CHF patients 
would have high cimutating levels of cTnl. Sere from 11 male end-stage CHF 
ps~isnts (mean age 46 :t: 11 years, mean LV ejection fraction 19.3 :E 5.9%), 
and from 11 healthy control subjects were assessed for cTnt using a highly 
specific slngis-alep immunoenzymomaldc assay without crossreactivity with 
the skeletal muscle isoforms (cut-off value 10 pg/mL, detection limit 3 pg/mL), 
High circulating levels of cTnt were found In all but one CHF patients. The 
median (25th, 75th percentile) serum cTni was 32 (15, 55) pg/mL, mean (SD) 
89 (166) WmL in CHF patients and belOw the detection limit of the assay 
in control subjects 0 (0, 5) pg/mL, mean (SD.) 2.9 (3.8) pg/mL, p = 0.gg0t. 
Furthermore, oTnl was strongly associated with LV eje~on fraction in CHF 
patients (R = -0.70, p = 0.01): the higher the cTnl levels, the lower the 
ejection fraction. This study provides the first evidence for elevated serum 
cTnl in human end-ctage CHF. cTn[ is a reliable cardiac-specific marker 
molecule that could be used for screening and risk-assessment in CHF 
patients. 
~- '~ Evaluation of  Magnitude of  Effect and Si,t;e of  
Action of Oopamine on the Renal Circula,~ion in 
Patients With Heart Fellure With the Aid of 
Intravescuiar Ultrasound and Doppler Techniquee 
Ud Elkeyam, Sameh Gedallah, Anilkumar Mehra, Rejendra Vallabhaneni, 
Janet V. Johnson. USC SchoM o/ Medicine, Los Angeles, CA 
Although "renal dose* dopamine is often used to increeso renal blood flow 
(RBF), data on magnitude of effect and sits of action are scarce. We evaluated 
the renal effect of intravenous dopamlne in doses of 1, 2, 3, 5 and 10 
mcg/kg/mln in 11 pts with chronic heart failure (CHF) undergoing cardiac 
catheterization. Effect on mean renal artedat pressure (RAP), renal artery 
cross sectional area (CSA), renal vascular resistance (RVR) and F'=JF were 
assessed. CSA was measured by intravascular ultrasound and renal artery 
flow velocity by intravascular Doppler, The effects were as follows: 
FlAP CSA RVR RBF 
(mmHg) (cm 2) (dynes) (ml/min) 
Baseline 95 ± 5 0.256 :E 0.02 16243 ±1861 475 ± 64 
1 mcg~min 93:~5 0.268 ~: 0.02 13248 ±t796" 608±98 
2 mcg/kg/m|n 93±6 0.285 • 0.02 11785±1728" 711:~141 
3 mcg/kg/mtn 96 :t: 5 0.290 ± 0.02 10218 =t: 1362" 74e :E 70* 
5 mcg/kg/mln 100 ± 4 0.299 ~: 0.02 9359 .+. 1385* 8764- 99' 
10 mcg/kg/mln 1024-11 0,268 d: 0.0A 10014±1996' 765:1:133" 
• p < 0.05 vs baseline 
Conclusions: 1) Dopamlne at 3-10 mng]kg/min results in a significant 
augmentstion of RBF in pts with CHF with a maximum effect of 108 :E 30% 
at 8 mcg/kg/min; 2) marked increase in RBF in spite of only a small and 
statistically insignificant increase in CSA suggest dilation of renal resistance 
vessels as a predominant site of dopamine effect on the renal circulation, 
~ Cacmoxirole, a Novel Selective DAe-Receptor 
Agoniat, Acutely Reduces Neurohormonal  
Activation and Improves Cardiac Function in 
Moderate to Severe Heart Failure 
Martin van der Ent, Ad F.M. van den Heuvel, Wlitem J. Remme. Sticares 
Foundation, Rotterdam, The Nethedands 
In heart failure therapy, one of the novel approaches concerns further modu- 
lation of neurohormonal ctivation in addition to ACE inhibition. EMD 45609 
(carmoxireta, C), a DAe-recepter agonist with limited central activity, modu- 
lates sympathetic activation and subsequently reduces pro- and afterloed. 
As the effect of a specific DAe-agnnist has not been studied yet in heart 
failure patients, the effect of C on neumhermones and hemodynamics was 
evaluated in 12 normotsnsive patients with NYHA cl Ill-IV heart failure on sta- 
ble ACE-inhibitor and diuretic therapy. C (0.25-1.00 rag) was administered 
on 2 consecutive days, and hemodynamio and neumhormunal measure- 
men~ carded out, Values given am maximal % changes ,'ram baseline (p 
< 0.05). The lower dose on day I (0.25-0.50 rag) reduced circulating nore- 
pinephdne, vesOpressin and ANF by 40%, 19°/,, and 25%, rasp. In addition, 
on day 2, at a dose level of 0.75-1.00 rag, plasma renin activity decreased 
by 30%. Changes in other neurohormones were comparable to day 1. C 
dose-dependenhy reduced mean arterial pressure and systemic resistance 
by 10% and 18%, rasp. Pulmonary wedge and dght atrial pressure fell by 
38% and 39"/=, rasp. Cardiac pump function improved with a maximal 20% 
inorease in cardiac index. Despite a concomitant 12=/o reduction in heart rate, 
both stroke volume and stroke work increased by 32% and 31%, rasp. Mean 
pulmonary artery pressure decreased by 21%. Thus, C significantly modu- 
lates sympathetic activation already at a low dose, accompanied by changes 
in vasopressin and ANF, and, at the high dose, in the renin-angiotansin sys- 
tem. These effects lead to a reduction in systemic vascular resistance and 
heart rate, and to an improvement inca:dies pump function and left and dght 
ventdcular filling pressures, already at the lowest dose level. It is concluded 
that selective DA~ agonists such as carmokirele may be a useful addition to 
heart failure treatment through their neurohormona! modulating effects. 
~ Aldosterene in Syndromes of  Untreated 
Congestive Heart Failure 
lnder S. Anand, Y. Chandrashekhar, Roberto Ferrad, Philip Poota-Wlison, 
Peter Herds. VA Medical Center, Minneapolis, MN; National Heart & Lung 
Institute, London, UK 
Serum aldosterone is elevated in some patients with congestive heart failure 
(CHF) but its role in the pathogenesis of CHF is unclear, Aldostemne causes 
sodium retention, stimulates fibrous tissue proliferation in the heart after 
myocardial infarction and may, therefore, influence the natural history of 
heart failure. Aldosterone levels are also known to be significantly altered 
by drugs used in the treatment of CHR In view of this, we moesured and 
correlated serum aldosterone levels with hemodynamios, plasma hormones 
[norepinephrine, plasma renin activity (PRA) & ANF], total body water (TBW), 
total body exchangeable sodium (TBNa) and effective renal plasma flow 
(ERPF) In untreated patients with different syndromes of CHF: Low output 
heart failure due to systolic dysfunction (untreated ilated cerdlomyopathy, n 
= 7) & diastolic dysfunction (untreated constrictive pericarditis, n = 15), and 
high output failure (chronic or pulmonale, n = 9). Aldosterene was markedly 
irmreased in patients with untreated low output systolic CHF (330 =t: 122 
pg/ml, normal 52 :t: 7 pg/ml, p = 0,02) and correlated strongly with PRA (r 
= 0.87, p < 0.01) but not with other hormones, hemodynamics, TBW, TBNa 
or ERPR In patients with low output diastolic heart failure, aldosterone was 
moderately elevated (178 ± 42 pg/ml, p = 0.003) & correlated with PRA (r = 
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0.78, p < 0,003), TBW (r = 0.6, p < 0.03), and TBNa (r - 0.7, p < 0,001). In 
patients with high output CHF, aldosterone was not elevated but correlated 
with PRA (r = 0.8, p < 0.02) and ERPF (r = -0,75, p < 0.003). When all 
the gmupe were taken together, aldoaterone cantinued to correlate strongly 
with PRA but now a weak correlation emerged with fight atrial (r = 0.46, p 
< 0,02) and pulmonary wedge (r = 0.45, p < 0.98) pressures and cardiac 
output (r = -0,43, p < 0.03). We conclude that aldestemne is elevated In 
patients with untreated !ow but not high output CHF. It correlates weft with 
PRA in ;dl groups suggesting that PRA continues to determ~e aldesterone 
levels even in such diverse cfini(~J states but poorly with ind~oes of eait and 
water retention. 
~ Neurohumoml Activation and Hemodllution Under 
Pamntsm] AdmlnlstrM~ion o f  MolMdomine and 
Isosorbide Mononitrate 
Ids Haehnet, Andrea Beyerle~ Guentor Lehmann, Guenther Rei~er, 
Wemer Koch, Wemer Rudolph. German Heart Center Munich, Germany 
Hemnditution and neumhumoml activation folk~vAng vasodilation are thought 
to be major factors for the development of nitrate toiem.aree. To determine 
whether these mach~lisms are part of the action profile of molsidomine (M), 
we investigated the hemodynamlcs, neurohumora! activation, and hemndi- 
lution dudng i,v. administration of M and isosod~de-5-monenitrate (I) in 15 
patients with CHF (NYHA I1-111). In a randomized, double-blind, cross-over 
design, each patient received a 24-hour ;nfusion of M (6 rng/h), I (3.75 ms/h) 
and placebo (P). Measurements were gerlormed at baseline, at 2 h, at 8 h, 
end at 24 h. Resu~ (mean ± SEM): Both vasndflators caused a continuous 
increase in plasma volumes with a maximum at 24 h: I +8.2 :l: 2.2°/,, (p < 
0.0001), M +18,5 -4- 2.7% (p < 0.0001). Plasma volumes did not change on 
placebo. The plasma renln activity (ng/ml/h) is shown below: 
Baseline 2h 8h 24h 
P 7.50 ~2.37 6.954-2`29 7.82d12`17 7.53-=-2.41 
! 7.71 =~ 2.32 S.51 ~2.62 ° 10.151112.32 =~ 8.20 • 2.14 # 
M S.53 ~ 2.17 12.01 ±2A9 °=° 15.36 ~ 2.65 °°°d 12.51 ~- 2.74 **°°~ 
*p < 0.05, "p  < 0.01 (vs P), °p < 0S, °°p < 0,001 {vs baseline) #p < 0.05 (I vs M) 
Levels of Angiotensin ti, ald0stemne and vasopressin did not change 
significsntiy. Hemodyr~mtcaJly, a significant improvement of CO and diastolic 
PAP was observed at 2 h on both treatments, This effect was maln~ned on 
Mat8hand24h (p < 0.05), but not on t. 
Conclusion: Continuous infusion of ! led only to a moderate hemodilutir)n 
and noumhumorel activation, but developmem of toierence was observed 
starting at 8 h. In contrast, edministmtion of M resulted in prolonged hemo- 
dyr~mlc effects, at!hough pmn¢.,unced changes in plasma volume and nou- 
rohumorat activation occurred. We conclude '.hat tn~l  Tluid shift end/or 
neurohumoml activetiol~ is not a major factor in the development of nitrate 
tolerance. 
~ Haemodynamical Effects o f  L-Camltlne on 
Patients With Congest ive Heart Failure Due to 
Dilated Cardiomyopathy 
leannis K, RIzos, Ads!elates N, Pdmiklrepoalos, Leonidas K, Hadjlalkolaou, 
Kestes I. Kapetanios, Solids C, $lamou, Petros D, Papa~poulos, Pavlos 
K, Toutouzas. Department of Cardiology, Unk, em#y of At~.ns, Athens, 
Greece 
The haemodynamtcsl effects ol L-Camitine (LC) were studied on 34 patients 
(pts) in a double blind study. Pts with dilative cardiomyopethy (CM) and 
clinical stable heart failure (HF) (NYHA Ill-IV) wore included in the study. 
All pie underwent left and right cardiac cathetedzatien (CC) and cardiopul- 
monary exercise test (CPX) according to Weber protocol, in a baseline (BL) 
examination. After one (1M) and three months (3M) treatment ~lh placebo 
(18 pts) and LC (2 g/die per os)(16 pte) right CC and CPX were repeatod. 
All conventional drugs for HF remained unchanged dudng the study. The 
following mean values were determined prior to (b) and after Ca) CPX: max- 
imal time of CPX (CPX-T) (rain), peak 02 consumption (VO2) (ml/mtrVKg), 
artertal~utmonary blood pressure (ABP/PBP) (mmHg), cardiac output (CO) 
(L/min). 
Results: 
Ptacet~ L-camitlne 
BL 1M 3M BL 1M 3M 
CPX-T 7.2 6.8 7.0 8.2 9A* 9.5" 
VO2 12,3 11.0 11.2 13.2 1,~.3" 14,0" 
ABP(b){8/D) 128/85 133/87 131/82 127/83 115/78" 133/83 
ABP(a)(SiD) 142/96 151/94 166/96 150/92 154/95 165/95 
PBP~)(S/D) 37113 36/17 38/18 34/12 26/8" 32/12 
PBP(a)(S/D) 42/17 42/12 41114 41114 38/12 40113 
CO(b) 4.2 4.3 4.1 4.2 4.4 4.2 
CO(a) 7,8 7.9 7.8 7.0 9.5' 9,8 ° 
b-~stolic/dbslollc (S/D), "p < 0.01, p~cebo vs L-cam!line 
Conciusions: LC has improved C,O and increased the duration of CPX. V02 
was increased in one as well In 3 months alter LC administration, thereby 
improving the functional status. 
Coronary Heart Disease in the Elderly: 
Evaluation, Management, an¢l Outcomes 
Wednesday, March 27, 1996, 9:00 a,m.-11:00 a.m. 
Orange County Convent ion Center, Hall E 
Presentation Hour:  10:00 a.m.-11:00 a.m. 
~'~' ]  Stents in the Elderly for  Failed PTCA, Early and 
Intsmmdlate Temt Results 
Randall C. Thompson, Kirk N. GarratL Peter B. Berger, Diane Eo Gdll, David 
R, Holmes, Jr., Mayo Clinic, Jacksonville, FL: Mayo Clinic, Rochester, MN 
In order to determine relative acute and intermedtate-~'m outcomes, 113 
patients (pie) over age 65 undergoing iotresorcoa~ stem placemem for 
acute or threatened artery closure during percutenenus Uanstun~nel coronary 
engioplesty (PTCA) were compared with 74 pts < 65 y receiving stents and 
with 1,602 pts > 65 y he, ring non-emergent PTCA, 1988 through 1994. 
Compared with the younger pts end the elderly PTCA pts. the older stent 
pts hed similar important baseline chsmcteristics. The techeicat success rate 
was high in ~! three ~ ,  89,4% ek~ stent group, 93.2% younger stent 
group, 90.9% eklerly PTCA pts (p = NS) and the rate of emergency bypass 
surgew was low; 2.7%, 5.4%, and 1.1% respectively (p = NS). The rate of 
mortality for the elderly stem 10is was 4,4% vs 0% for stem pts < 65 y (p 
= 0.067) and 2.2% for PTCA pie _> 65 y (p = NS). The in-hospital MI rate 
was 3.5% for elderly stent ptevs 2.7% ter stent pts < 65 (p = NS) and 0.8% 
aldedy PTCA group Lo < 0.003). The incidence of bradycar~a was higher 
in the eldedy etent pte (11.5%) than younger stent pts (1.4%)(p < 0.01) or 
the elderly PTCA pts (4.1%)(I) < 0.001). The eldedy stent group also had 
a more frequent need for blood transfusion (25.7%) and higher incidence of 
renal insufficiency (P_.7%) vs the elderly PTCA group (6.1%, p < 0.0001 and 
0.5%, p < 0.05), 10ut not compared with the younger etent group (21.6% and 
0%, p = NS). 
Survival free of MI was high for at! three groups, 91.7% elderly stem pts, 
98.3% younger stent pts, and 90.5% elderly PTCA lots at one year. 
Thus, in pie with stenla p~aced for PTCA failure, need for blond transfusion 
and cther ~ iar  complicatfon~J were frequent but in-hespilal and interme- 
diate term event free suwhtal were excellent in the elderly and is similar to 
that of e~=dy pts undergoing PTCA without need for sterile. 
~ OutcOme of  Right Ventricular Elderly In!am!Ion in 
Patients 
Hq~tor Bueno, Ras~n I~pez-Palop, Javisr BermeJo, Jce6 
L L0pez -~,  Juan L Dek~n. Hes/~at Genera/"Gregodo .V~ra~n" 
M~,  Spain 
It is known that, among patients (10is) with inferior myocard~ infarction, those 
who develop right ventdcular infarction (RVI) have a worse prognosis, and 
that LV diastolic: dysfon.'~on is a common feature in elderly pie, in whom 
cardiac output is more debende~t on LV filling presure. Them!ore, it might 
be as t~ted  that RVI should have a pmlicuia~'ly negative e,~ent in the 
hemodycamlca of inferior AMI in eldedy tots. To confirm this hypothesis and 
to investigate its dialcaJ s ign~,  we studied the in-hospital outcome of 78 
consecutive pts > 75 years old admitted to the CCU with a first AMI of inferior 
location. We cempamcl the pie with ECG or echocardiogrephic evidence of 
RVI (n = 30, 38%) with those without RVL Baseline characteristics were 
S~,niiar in heth greups except for age, which was higher in pie with RVI (81 vo 
79 yea~ old, p = O.Ot). LV ejection fraction did not significentiy differ in both 
groups {0.47 in 10ts without RVI vs 0.43 tn pts with RVI). The most ~;ignlficsnt 
results are show~ in the table. 
